Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesFRA:82P +1.77%77 EV-to-EBIT is 46.43 as of Aug. 03, 2026, which is 13% above its 10-year median of 41.25. GuruFocus rates FRA:82P with a GF Score™ of 77/100 and a GF Value™ of €26.05. The stock has 8 warning signs investors should review. Among 691 Drug Manufacturers companies, Pacira BioSciences ranks worse than 84.23% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pacira BioSciences's Enterprise Value for the quarter that ended in Mar. 2026 was €963.1 Mil.
Pacira BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences EV-to-EBIT Related Terms
Pacira BioSciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ALVO, BIOA, COLL: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's EV-to-EBIT falls into.
Pacira BioSciences's current Enterprise Value is €1,083.2 Mil.
Pacira BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a EV-to-EBIT of 46.43 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pacira BioSciences and its competitors. This is 13% above median its historical median of 41.25. According to the industry distribution chart, Pacira BioSciences ranks #582 out of 691 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Pacira BioSciences' EV-to-EBIT too high?
Pacira BioSciences' current EV-to-EBIT of 46.43 is 13% above median its 10-year median of 41.25. The Drug Manufacturers industry median EV-to-EBIT is 15.59. Pacira BioSciences' value of 46.43 is 197.8% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #582 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' EV-to-EBIT compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #582 out of 691 companies for EV-to-EBIT. This places Pacira BioSciences in the lower half of its industry. The industry median EV-to-EBIT is 15.59. Pacira BioSciences' value of 46.43 is 197.8% above this benchmark. While the company's 10-year median is 41.25 vs. the industry median of 15.59, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.59, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current EV-to-EBIT of 46.43 is 197.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current EV-to-EBIT is 46.43, which is 13% above median its own 10-year median of 41.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current EV-to-EBIT of 46.43. The stock's GF Value™ is €26.05, compared to a current price of €23.00 — trading 11.7% below its estimated fair value. The current EV-to-EBIT is 46.43, which is 13% above median its 10-year median of 41.25 and 197.8% above the Drug Manufacturers industry median of 15.59. Pacira BioSciences' overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current EV-to-EBIT is 46.43 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €23.00 is trading 11.7% below its estimated GF Value™ of €26.05.
Key valuation signals for FRA:82P:
EV-to-EBIT: 46.43 (13% above median its 10-year median of 41.25)
GF Value™: €26.05 vs. price of €23.00 (11.7% below fair value)
Industry Position: 197.8% above the Drug Manufacturers median (#582 of 691)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
77GF Score
Get the complete analysis for FRA:82P
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
